Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (11-20 of 275) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2018
<i>HER2</i> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?Federico Cappuzzo, Lorenza Landi
Annals of Translational Medicine|March 28, 2015
Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancerLorenza Landi, Federico Cappuzzo
Expert Opinion on Drug Safety|September 13, 2011
Gefitinib for non-small-cell lung cancer treatmentArmida D'Incecco, Federico Cappuzzo
Biologics : Targets & Therapy|March 16, 2013
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
Journal of Thoracic Disease|July 27, 2012
Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?Lorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research|March 26, 2015
EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMationLorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research|March 26, 2015
Irreversible EGFR-TKIs: dreaming perfectionLorenza Landi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|May 31, 2002
Gemcitabine in non-small cell lung cancerLucio Crinò, Federico Cappuzzo
Therapeutic Advances in Respiratory Disease|June 12, 2015
Experience with erlotinib in the treatment of non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Nature Reviews. Clinical Oncology|September 1, 2011
Targeted therapies: Front-line therapy in lung cancer with mutations in EGFRLorenza Landi, Federico Cappuzzo
Pageof 28

Showing results (11-20 of 275) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2018
<i>HER2</i> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?Federico Cappuzzo, Lorenza Landi
Annals of Translational Medicine|March 28, 2015
Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancerLorenza Landi, Federico Cappuzzo
Expert Opinion on Drug Safety|September 13, 2011
Gefitinib for non-small-cell lung cancer treatmentArmida D'Incecco, Federico Cappuzzo
Biologics : Targets & Therapy|March 16, 2013
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancerManolo D'Arcangelo, Federico Cappuzzo
Journal of Thoracic Disease|July 27, 2012
Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?Lorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research|March 26, 2015
EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMationLorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research|March 26, 2015
Irreversible EGFR-TKIs: dreaming perfectionLorenza Landi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|May 31, 2002
Gemcitabine in non-small cell lung cancerLucio Crinò, Federico Cappuzzo
Therapeutic Advances in Respiratory Disease|June 12, 2015
Experience with erlotinib in the treatment of non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Nature Reviews. Clinical Oncology|September 1, 2011
Targeted therapies: Front-line therapy in lung cancer with mutations in EGFRLorenza Landi, Federico Cappuzzo
Pageof 28